Ignite Creation Date:
2025-12-25 @ 12:27 AM
Ignite Modification Date:
2026-02-24 @ 4:11 AM
Study NCT ID:
NCT01833767
Status:
WITHDRAWN
Last Update Posted:
2017-08-24
First Post:
2013-04-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D008545', 'term': 'Melanoma'}], 'ancestors': [{'id': 'D018358', 'term': 'Neuroendocrine Tumors'}, {'id': 'D017599', 'term': 'Neuroectodermal Tumors'}, {'id': 'D009373', 'term': 'Neoplasms, Germ Cell and Embryonal'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D009380', 'term': 'Neoplasms, Nerve Tissue'}, {'id': 'D018326', 'term': 'Nevi and Melanomas'}, {'id': 'D012878', 'term': 'Skin Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D003520', 'term': 'Cyclophosphamide'}, {'id': 'D007376', 'term': 'Interleukin-2'}], 'ancestors': [{'id': 'D010752', 'term': 'Phosphoramide Mustards'}, {'id': 'D009588', 'term': 'Nitrogen Mustard Compounds'}, {'id': 'D009150', 'term': 'Mustard Compounds'}, {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D063088', 'term': 'Phosphoramides'}, {'id': 'D009943', 'term': 'Organophosphorus Compounds'}, {'id': 'D007378', 'term': 'Interleukins'}, {'id': 'D016207', 'term': 'Cytokines'}, {'id': 'D036341', 'term': 'Intercellular Signaling Peptides and Proteins'}, {'id': 'D010455', 'term': 'Peptides'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D008222', 'term': 'Lymphokines'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D001685', 'term': 'Biological Factors'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 0}}, 'statusModule': {'whyStopped': 'No participants enrolled', 'overallStatus': 'WITHDRAWN', 'startDateStruct': {'date': '2012-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-08', 'completionDateStruct': {'date': '2015-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-08-22', 'studyFirstSubmitDate': '2013-04-14', 'studyFirstSubmitQcDate': '2013-04-14', 'lastUpdatePostDateStruct': {'date': '2017-08-24', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2013-04-17', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Response Rate', 'timeFrame': 'One year'}], 'secondaryOutcomes': [{'measure': 'Median Survival', 'timeFrame': 'One year'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Metastatic Melanoma']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine response rates by administering low dose cyclophosphamide on day 1, followed by 5 days of outpatient IL2.', 'detailedDescription': 'To determine the response rate, median duration of response and median survival of patients treated with this low-dose cyclophosphamide + moderate dose bolus Interleukin-2 schedule.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Patients must have a histologic diagnosis of metastatic melanoma. Patients may have received prior systemic therapy or may be previously untreated.\n2. Patients must have measurable disease on physical exam or radiologic studies.\n3. ECOG performance status of 0 or 1 and estimated survival of at least 3 months.\n4. White blood count of \\> 3500/mm3, platelet count \\> 100,000/mm3, hemoglobin \\> 9.0 gm/dl; bilirubin, ALT, AST \\< 3 x upper limit of normal; serum creatinine \\< 2.0 mg/dl.\n5. Patients must undergo a low-level cardiac stress test as a screen for possible atherosclerotic heart disease. Patients with a positive stress test would be excluded from this trial.\n6. Patients with elevated temperatures \\> 100.5 F must have sources of occult infection excluded.\n7. Patients must be felt to have recovered from effects of prior therapy, such as \\> 2 weeks after prior chemotherapy.\n8. Women of childbearing potential must have a negative pregnancy test and adequate precautions to prevent pregnancy during treatment must be taken.\n9. Patient consent must be obtained prior to entrance onto study.\n\nExclusion Criteria:\n\n* 1\\. Medical illness requiring corticosteroids or other immunosuppressive agents (such as cyclosporin or methotrexate.\n\n 2\\. Autoimmune disease such as inflammatory arthritis which could be exacerbated by immune-based therapy.\n\n 3\\. Prior history of psychiatric disorder which could be exacerbated by interleukin-2.\n\n 4\\. Lactation or pregnancy.\n\n 5\\. Evidence of significant cardiovascular disease including history of recent (\\< 6 months prior) myocardial infarction, congestive heart failure, primary cardiac arrhythmias (not due to electrolyte disorder or drug toxicity, for example) beyond occasional PVC's, angina, positive low-level stress test, or cerebrovascular accident.\n\n 6\\. Current untreated brain metastasis."}, 'identificationModule': {'nctId': 'NCT01833767', 'briefTitle': 'Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma', 'organization': {'class': 'OTHER', 'fullName': 'Western Regional Medical Center'}, 'officialTitle': 'Phase 2 Trial of T-cell Based Low-dose Cyclophosphamide and Outpatient Intravenous Interleukin-2 in Metastatic Melanoma', 'orgStudyIdInfo': {'id': '12-12'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cyclophosphamide and Interleukin-2', 'description': 'Cytoxan IV on day 1, IL2 IV on days 1-5', 'interventionNames': ['Drug: Cyclophosphamide and Interleukin 2']}], 'interventions': [{'name': 'Cyclophosphamide and Interleukin 2', 'type': 'DRUG', 'otherNames': ['Cytoxan', 'IL2'], 'description': 'Cytoxan IV day 1, IL2 IV days 1-5', 'armGroupLabels': ['Cyclophosphamide and Interleukin-2']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85338', 'city': 'Goodyear', 'state': 'Arizona', 'country': 'United States', 'facility': 'Western Regional Medical Center Inc', 'geoPoint': {'lat': 33.43532, 'lon': -112.35821}}], 'overallOfficials': [{'name': 'Walter Quan, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Western Regional Medical Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Western Regional Medical Center', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Research Director', 'investigatorFullName': 'Jordan Waypa', 'investigatorAffiliation': 'Western Regional Medical Center'}}}}